New allergenic molecules in state-of-the-art multiplex macroarray immunoassay

The multiplex macroarray immunoassay, as a state-of-the-art molecular allergology explorer, represents the most advanced diagnostic system for the molecular diagnosis of IgE-mediated allergies, providing a complete IgE reactivity profile by simultaneously analyzing 300 allergen specificities (218 molecules and 82 extracts) from a single serum sample. This technology uses nanoparticles to preserve epitopes and a cross-reactive carbohydrate determinant inhibitor to ensure high specificity and eliminate false-positive results. The 2025 update, based on big-data analysis of over 400,000 clinical cases, introduces essential biomarkers, such as α-Gal, chitinases and new storage proteins, facilitating a clear distinction between primary sensitization and cross-reactivity. This indispensable tool for precision allergy management enables risk stratification and optimizes patient selection for allergen immunotherapy.